Anti-TNF-α therapy for ankylosing spondylitis

Clinics in Orthopedic Surgery

Volumn 2, Issue 1, 2010, Pages 28-33

  Son, Jung Hwan ^a   Cha, Sang Won ^a  

^a Kosin University   (South Korea)

Author keywords

Ankylosing spondylitis; Etanercept; Tumor necrosis factor alpha

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DRUG ADMINISTRATION; DRUG ANTAGONISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77954555197     PISSN: 2005291X     EISSN: 20054408     Source Type: Journal    
DOI: 10.4055/cios.2010.2.1.28     Document Type: Article

References (11)

1. Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curr Opin Rheumatol. 2003;15(4):394-407.
2. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol. 2001;13(4):245-9.
3. Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67(3):346-52.
4. van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68(3):362-6.
5. Reed MR, Taylor AL. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern Med J. 2008;38(10):781-9.
6. Liu Y, Cortinovis D, Stone MA. Recent advances in the treatment of the spondyloarthropathies. Curr Opin Rheumatol. 2004;16(4):357-65.
7. Song JS. Review of tumor necrosis factor inhibitors on rheumatoid arthritis. J Korean Rheum Assoc. 2007;14(1):1-14.
8. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents: a guide for GPs. Aust Fam Physician. 2007; 36(12):1035-8.
9. Yun HR, Kim TJ, Kim TH, Choi HS, Bae SC. Anti-TNFalpha therapy in rheumatic diseases with chronic hepatitis B virus infection. J Korean Rheum Assoc. 2007;14(3):242-50.
10. Her MY, Sheen D, Kim TH. Treatment of ankylosing spondylitis. J Korean Rheum Assoc. 2006;13(1):1-9.
11. Howe CR, Gardner GC, Kadel NJ. Perioperative medication management for the patient with rheumatoid arthritis. J Am Acad Orthop Surg. 2006:14(9):544-51.